|
ИСТИНА |
Войти в систему Регистрация |
ИПМех РАН |
||
Tamoxifen Never Ceases to Amaze: New Findings on Non-Estrogen Receptor Molecular Targets and Mediated Effectsстатья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 4 марта 2022 г.
- Авторы: Bogush Tatiana Anatolievna, Polezhaev Boris Borisovich, Mamichev Ivan Andreevich, Bogush Elena Alexandrovna, Polotsky Boris Evseevich, Tjulandin Sergei Alexeevich, Ryabov Andrey Borisovich
- Журнал: Cancer Investigation
- Том: 36
- Номер: 4
- Год издания: 2018
- Издательство: Marcel Dekker Inc.
- Местоположение издательства: United States
- Первая страница: 211
- Последняя страница: 220
- DOI: 10.1080/07357907.2018.1453933
- Аннотация: Tamoxifen is a first targeted drug that continues to be the gold standard in treatment of estrogen receptor positive breast cancer for almost 50 years. The current review is an update of the paper published in 2012. We provide the new data on the tamoxifen targets that are the key points of signaling cascades activating cellular proliferation, which determines aggressiveness of disease and chemotherapy resistance or sensitivity. Some inspiring clinical cases dealing with tamoxifen efficiency in treatment of different tumors are discussed. Additionally, the review includes data on antiviral, antibacterial, antifungal and antiparasitic activity of tamoxifen.
- Добавил в систему: Тюляндин Сергей Алексеевич